About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

The "Seizures Pipeline Insight Analysis Report" drug pipelines has been added to ResearchAndMarkets.com's offering.The Seizures treatment pipeline analysis provides an overview of recent advancements ...

Novartis' dividend yield currently stands at 3.58%, which is significantly higher than that of the healthcare sector. Read ...

Syngenta is continuing to grow its biologicals division with the recent acquisition of certain Novartis technologies.

Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...

Novartis has announced that it will be expanding its late-stage cardiovascular pipeline by acquiring Anthos Therapeutics for ...

Basel, February 11, 2025 – Novartis today announced that it has entered into an agreement to acquire Anthos Therapeutics, Inc., a Boston-based, privately held, clinical-stage biopharmaceutical ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Novartis Indias NEST competition culminates in a showcase of innovative healthcare solutions, highlighting the talent of ...

Now is the right time to bring abelacimab back into the Novartis CRM pipeline.” Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor ...

If approved, Fabhalta® will be the only medicine indicated to selectively target the underlying cause of C3G1, an ultra-rare, progressive kidney disease with no currently approved treatments2-5 Phase ...

We recently compiled a list of the 10 Cheap Pharmaceutical Stocks to Buy According to Analysts. In this article, we are going ...